WHY WE ARE UNIQUE

BREAST CANCER ALLIANCE is making a national impact as one of the most prominent, private non-corporate breast cancer organizations in the United States.

WE HAVE FUNDED 491 GRANTS TO DATE

We continue to improve the outlook on breast cancer and are proud to have funded so many impactful grants and groundbreaking research despite the pandemic. With the uncertainty of federal funding, the need for private philanthropy for the advancement of cures continues to grow.

1. WE FOCUS ON CRUCIAL EARLY-STAGE RESEARCH.
   Breast Cancer Alliance is a premiere private foundation committed to funding early-stage, innovative and impactful research not yet eligible for federal grants. BCA uniquely bridges that gap by providing exceptional researchers with scientific venture capital, propelling life-changing scientific hypotheses from the conceptual stage to reality.

2. WE SUPPORT BRILLIANT TALENT IN THE FIELD.
   Breast Cancer Alliance understands that survival rates and quality of life are dramatically improved when patients are in the care of specially-trained breast surgeons. As a result, BCA uniquely funds breast surgery fellowships at Society of Surgical Oncology-accredited institutions. These highly skilled surgeons go on to work at institutions across the United States. Through its Young Investigator Grants, BCA helps launch the careers of promising new scientists as well.

3. WE ELIMINATE BARRIERS OF ACCESS TO ESSENTIAL BREAST CARE.
   Breast cancer survival rates are near 90% due to advances in early detection and improved education. BCA funds breast health education programs and covers costs associated with mammograms, biopsies and other breast cancer-related services, lessening the burden for underserved patients.

**THIS YEAR’S GRANT RECIPIENTS ARE:**

**EXEMPLARY PROJECT GRANTS**
- Barbara Fingelton, PhD, Vanderbilt University, Type II IL4 receptor blockade as a strategy for treating breast-to-brain metastasis
- Supported by Tap Cancer Out
- Hyungjin Kim, PhD, SUNY Stony Brook, DNA replication fork instability as a target for the synthetic lethality of breast cancer
- Supported by the Jeffery family in honor of Karen Lowney
- David Rimm, PhD, Yale University, Budding Carcinogenesis; a novel pathway to malignancy
- Supported by Veronica Beard
- Anna C. Weiss, PhD, Brigham and Women’s Hospital, The Impact of Neoadjuvant Endocrine Therapy on Breast Cancer Axillary Outcomes
- Supported by Jane and Stuart Wetzman in memory of Irma Wallin

**YOUNG INVESTIGATOR GRANTS**
- Raymond Acclivatit, PhD, University of Pennsylvania, Self-Steering 3D Mammography
- Supported by Stacia and Gary Smith
- Ana Christina Garrido-Castro, PhD, Dana Farber Cancer Institute, Studying the evolutionary dynamics of tumor and immune microenvironment in triple-negative breast cancer
- Ryan Stowers, PhD, University of California – Santa Barbara, Understanding Epigenomic remodeling induced by tumor mechanical properties
- Jessalyn Ubellacker, PhD, Harvard University, Targeting metabolic vulnerabilities of breast cancer metastasis in lymph
- Alexander Vallevezan, PhD, Rutgers University, Targeting triple-negative breast cancer by exploiting a metabolic vulnerability downstream of mTORC1

**BREAST SURGERY FELLOWSHIPS**
- Shridevi Singh, MD, Rutgers Cancer Institute of New Jersey, Rodkin Family Fellow
- Anna C. Beck, MD, Memorial Sloan Kettering Cancer Center, Tap Cancer Out Fellow

**EDUCATION AND OUTREACH GRANTS**
- Bridgeport Hospital, Bridgeport, CT
- Danbury Hospital/ New Milford Hospital, Danbury & New Milford, CT
- Gilda’s Club Westchester, White Plains, NY
- Greenwhich Hospital, Greenwich, CT
- Griffin Hospital, Derby, CT
- Hartford Hospital, Hartford, CT
- Hospital of Central Connecticut, New Britain, CT

**Supporting Institutions**
- New Britain, CT
- Connecticut, Hartford, CT
- White Plains, NY

**Annual Meeting**
- Meeting with our grantees to learn about the research we underwrote

**Funding screening for the underserved**

---

Educating our supporters with leading experts at our medical symposium